Ines Frank

Ines Frank

Auto-generated profile, based on publicly available information

Ines Frank

Center for Biomedical Research, Population Council, New York, NY, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 November 2022 in JCI Insight
Verified
Journal Article
Open access
PDF file
SSSadia Samer
Sadia Samer
YTYanique Thomas
Yanique Thomas
MAMariluz Araínga
Mariluz Araínga
CCCrystal Carter
Crystal Carter
LSLisa M. Shirreff
Lisa M. Shirreff
EMElena Martinelli
Elena Martinelli
TGF-β plays a critical role in maintaining immune cells in a resting state by inhibiting cell activation and proliferation. Resting HIV-1 target cells represent the main cellular reservoir after long-term antiretroviral therapy (ART). We hypothesized that releasing cells from TGF-β–driven signaling would promote latency reversal. To test our hypothesis, we compared HIV-1 latency models with and without TGF-β and a TGF-β type 1 receptor inhibitor, galunisertib. We tested the effect of galunisertib in SIV-infected, ART-treated macaques by monitoring SIV-env expression via PET/CT using the 64 Cu-DOTA-F(ab′) 2 p7D3 probe, along with plasma and tissue viral loads (VLs). Exogenous TGF-β reduced HIV-1 reactivation in U1 and ACH-2 models. Galunisertib increased HIV-1 latency reversal ex vivo and in PBMCs from HIV-1–infected, ART-treated, aviremic donors. In vivo, oral galunisertib promoted increased total standardized uptake values in PET/CT images in gut and lymph nodes of 5 out of 7 aviremic, long-term ART-treated, SIV-infected macaques. This increase correlated with an increase in SIV RNA in the gut. Two of the 7 animals also exhibited increases in plasma VLs. Higher anti-SIV T cell responses and antibody titers were detected after galunisertib treatment. In summary, our data suggest that blocking TGF-β signaling simultaneously increases retroviral reactivation events and enhances anti-SIV immune responses.

18 August 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
IFInes Frank
Ines Frank
MCMariasole Cigoli
Mariasole Cigoli
SAShoaib Arif
Shoaib Arif
MFMarissa Fahlberg
Marissa Fahlberg
SMStephanie Maldonado
Stephanie Maldonado
EMElena Martinelli
Elena Martinelli
Broadly neutralizing antibodies and an anti-α 4 β 7 monoclonal antibody prolong viral load control in SHIV SF162P3 -infected macaques.

19 August 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
IFInes Frank
Ines Frank
AAArpan Acharya
Arpan Acharya
NRNanda K. Routhu
Nanda K. Routhu
MAMeropi Aravantinou
Meropi Aravantinou
JHJustin L. Harper
Justin L. Harper
EMElena Martinelli
Elena Martinelli
The establishment of latent infection and poorly characterized viral reservoirs in tissues represent major obstacles to a definitive cure for HIV. Non-human primate (NHP) models of HIV infection are critical to elucidate pathogenic processes and an essential tool to test novel therapeutic strategies. Thus, the availability of novel assays to measure residual viral replication and reservoirs in NHP models may increase their utility in the search for an HIV cure. We developed a tat/rev induced limiting dilution assay to measure the frequency of CD4+ T cells that express multiply-spliced(ms)_SIV RNA in presence and absence of stimulation. We validated the assay using cell lines and cells from blood and lymph nodes of SIV infected macaques. In vitro, SIV/SHIV TILDA detects only cells expressing viral proteins. In SIV/SHIV-infected macaques, CD4+ T cells that express msSIV/SHIV RNA (TILDA data) were detected also in the setting of very low/undetectable viremia. TILDA data were significantly higher after stimulation and correlated with plasma viral load (pVL). Interestingly, TILDA data from early cART initiation correlated with peak and AUC pVL post-cART interruption. In summary, we developed an assay that may be useful in characterizing viral reservoirs and determining the effect of HIV interventions in NHP models.

21 August 2020 in Science Advances
Verified
Journal Article
Open access
PDF file
SYSidi Yang
Sidi Yang
GAGeraldine Arrode-Bruses
Geraldine Arrode-Bruses
IFInes Frank
Ines Frank
BGBrooke Grasperge
Brooke Grasperge
JBJames Blanchard
James Blanchard
EHEmmanuel Ho
Emmanuel Ho
Anti-α 4 β 7 monoclonal antibody–conjugated nanoparticles block integrin α 4 β 7 on intravaginal T cells in rhesus macaques.

22 November 2023 in JCI Insight
Verified
Journal Article
Closed access
PDF file
SSSadia Samer
Sadia Samer
YTYanique Thomas
Yanique Thomas
MAMariluz Araínga
Mariluz Araínga
CCCrystal Carter
Crystal Carter
LSLisa M. Shirreff
Lisa M. Shirreff
EMElena Martinelli
Elena Martinelli